Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Insulet Corporation    PODD

Delayed Quote. Delayed  - 09/28 10:00:00 pm
42.82 USD   -2.17%
09/27 INSULET CORPORA : to Announce Third Quarter 2016 Financial Results o..
09/15 Sleep Instrument Market 2016 - Lifescan, Medtronic, A&D Company, ..
09/13 INSULET : Enrolls First Patients in Clinical Trial for its Omnipod® ..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Insulet Corporation : Insulet Announces Commercial Agreement With Amgen

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/10/2013 | 10:10pm CEST

BEDFORD, MA -- (Marketwired) -- 12/10/13 -- Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced an agreement with Amgen Inc., the world's leading independent biotechnology company, for a five year commercial agreement to supply Amgen with a delivery device specifically designed around the unique delivery needs of biotechnology medicines.

"We are thrilled to advance our collaboration with Amgen to supply this version of our technology," said Duane DeSisto, President and Chief Executive Officer of Insulet.

DeSisto added that "Insulet's current device, the OmniPod®, is a unique drug delivery platform that provides the ability to vary rate at which medication is infused. With over 25 million OmniPods produced, our innovative product is the undisputed global leader in patch pump technology and provides a patient-friendly and cost effective drug delivery alternative."

About Insulet Corporation
Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its OmniPod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The OmniPod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and fully-automated cannula insertion. Insulet's subsidiary, Neighborhood Diabetes, is a leading distributor for diabetes products and supplies, delivered through a high touch customer service model. To read inspiring stories of people with diabetes living their lives to the fullest with OmniPod, visit our customer blog, Suite D: http://suited.myomnipod.com. Founded in 2000, Insulet Corporation is based in Bedford, Mass. For more information, please visit: http://www.myomnipod.com.

Forward-Looking Statement

This press release contains forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future, including those related to its arrangements with Amgen. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks associated with the Company's dependence on the OmniPod System; Insulet's ability to increase customer orders and manufacturing volumes; adverse changes in general economic conditions; impact of healthcare reform legislation; risks related to the implementation of a national mail-order competitive bid program; Insulet's inability to raise additional funds in the future on acceptable terms or at all; potential supply problems or price fluctuations with sole source or other third-party suppliers on which Insulet is dependent; failure by Insulet to retain supplier pricing discounts and achieve satisfactory gross margins; failure by Insulet to retain key supplier and payor partners; international business risks; Insulet's inability to obtain adequate coverage or reimbursement from third-party payors for the OmniPod System and potential adverse changes in reimbursement rates or policies relating to the OmniPod System; failure to retain key partner payors and their members; failure to retain and manage successfully Insulet'sMedicare and Medicaid business; potential adverse effects resulting from competition with competitors; technological innovations adversely affecting the Company's business; potential termination of Insulet's license to incorporate a blood glucose meter into the OmniPod System; Insulet's ability to protect its intellectual property and other proprietary rights; conflicts with the intellectual property of third parties, including claims that Insulet's current or future products infringe the proprietary rights of others; adverse regulatory or legal actions relating to the OmniPod System; failure of Insulet's contract manufacturers or component suppliers to comply with FDA's quality system regulations, the potential violation of federal or state laws prohibiting "kickbacks" or protecting patient health information, or any challenges to or investigations into Insulet's practices under these laws; product liability lawsuits that may be brought against Insulet; reduced retention rates; unfavorable results of clinical studies relating to the OmniPod System or the products of Insulet's competitors; potential future publication of articles or announcement of positions by physician associations or other organizations that are unfavorable to Insulet's products; the expansion, or attempted expansion, into foreign markets; the concentration of substantially all of Insulet's manufacturing capacity at a single location in China and substantially all of Insulet's inventory at a single location in Massachusetts; Insulet's ability to attract and retain key personnel; Insulet's ability to manage its growth; failure to integrate successfully the Neighborhood Diabetes business; intense competition among distributors of diabetes supplies impairing Neighborhood Diabetes' business; loss by Neighborhood Diabetes of an opportunity to sell insulin pumps supplied by Insulet's competitors; failure by Neighborhood Diabetes to retain key supplier and payor partners; failure by Neighborhood Diabetes to retain supplier pricing discounts and achieve satisfactory gross margins; failure by Neighborhood Diabetes to retain and manage successfully its Medicare and Medicaid business; existence of unanticipated liabilities arising in connection with the Neighborhood Diabetes business; fluctuations in quarterly results of operations; risks associated with potential future acquisitions; Insulet's ability to generate sufficient cash to service all of its indebtedness; the expansion of Insulet's distribution network; Insulet's ability to successfully maintain effective internal controls; the volatility of Insulet's common stock; risks related to future sales of its common stock or the conversion of the 3.75% Convertible Notes due June 15, 2016; potential limitations on Insulet's ability to use its net operating loss carryforwards; anti-takeover provisions in its organizational documents; and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 28, 2013 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

Contact:
Stephanie Marks for Insulet Corporation
ir@insulet.com
877-PODD-IR1 (877-763-3471)

Source: Insulet Corporation

News Provided by Acquire Media

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INSULET CORPORATION
09/27 INSULET CORPORATION : to Announce Third Quarter 2016 Financial Results on Novemb..
09/15 Sleep Instrument Market 2016 - Lifescan, Medtronic, A&D Company, Abbott Labor..
09/13 INSULET CORP : Creation of a Direct Financial Obligation or an Obligation under ..
09/13 INSULET : Enrolls First Patients in Clinical Trial for its Omnipod® Artificial P..
09/12 INSULET : PODD) Outlines Plans to Develop Automated Manufacturing Operation in U..
09/08 INSULET : Announces Pricing of Convertible Senior Notes Due 2021
09/06 INSULET CORP : Other Events, Financial Statements and Exhibits (form 8-K)
09/06 INSULET : Announces Private Offering of Convertible Senior Notes
09/06 INSULET : to Establish Highly-Automated Manufacturing Operation in the United St..
09/06 INSULET CORP : Entry into a Material Definitive Agreement (form 8-K)
More news
Sector news : Medical Prosthetics
02:46aDJMEDTRONIC : FDA Approves Medtronic's New Automated Insulin Pump -- Update
09/28DJMEDTRONIC : FDA Approves Medtronic's New Automated Insulin Pump
09/28DJMEDTRONIC : FDA Approves Medtronic's New Automated Insulin Pump
09/28DJMEDTRONIC : FDA Approves Medtronic's New Automated Insulin Pump
09/17DJJ&J to Buy Abbott Eye Business -- WSJ
More sector news : Medical Prosthetics
News from SeekingAlpha
09/21 INSULET CORP. : Pumped Up!
09/13 Feasibility study underway for Insulet's artificial pancreas system
09/08 Insulet prices upsized convertible debt offering
09/07 Insulet Issues New Convertible!
09/06 Insulet intends to float $250M in convertible debt in private offering
Advertisement
Financials ($)
Sales 2016 352 M
EBIT 2016 -13,7 M
Net income 2016 -30,5 M
Debt 2016 75,6 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 7,35x
EV / Sales 2017 6,28x
Capitalization 2 507 M
More Financials
Chart INSULET CORPORATION
Duration : Period :
Insulet Corporation Technical Analysis Chart | PODD | US45784P1012 | 4-Traders
Full-screen chart
Technical analysis trends INSULET CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 42,3 $
Spread / Average Target -3,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Patrick J. Sullivan President, CEO & Class III Director
Charles Alpuche Senior VP-Global Manufacturing & Operations
Michael L. Levitz CFO & Principal Accounting Officer
Michael P. Spears SVP-Quality, Regulatory & Clinical Affairs
Aiman Abdel-Malek Senior VP-Advanced Technology & Engineering
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
INSULET CORPORATION15.76%2 477
MEDTRONIC PLC12.68%119 620
STRYKER CORPORATION26.75%43 498
BECTON DICKINSON AND C..16.15%37 690
ESSILOR INTL.1.30%28 559
BAXTER INTERNATIONAL I..24.06%25 671
More Results